BASL
UK-PBC is a unique collaboration between patient groups, doctors, scientists and industry with a shared interest in increasing understanding about, and treatment for the autoimmune liver disease Primary Biliary Cholangitis (PBC).
PBC affects up to 20,000 people in the UK and whereas many do well with current therapy an important group of people have more aggressive liver disease that can lead to liver failure and the need for a liver transplant or other significant long-term complications.
PBC patients also experience important symptoms such as fatigue, itch and concentration problems that can significantly impair quality of life.
BASL